Look up an existing collection — by name, or by any study that used it — and see its valuation: the impact it has realized, the potential in its specimens, and the gap between the two.
Few teams can say what a collection is scientifically worth. Journal name and raw citation counts measure prestige and activity, not value — and they say nothing about the potential still locked in the samples.
The Biobank Advisor scores three things instead: the impact a collection has realized, the intrinsic potential of its specimens, and the gap between them — the single most actionable signal a steward can have.
The field-normalized impact of the science the specimens have produced — measured with citation ratios, not journal prestige.
The value of the specimens themselves — rarity, multi-omic depth, longitudinal follow-up, pre-diagnostic timing, consent breadth, and annotation quality.
The distance between specimen potential and realized impact — distinguishing an underexploited treasure from a collection that has been fully mined.
Where the looked-up collection lands against the valued registry (shown coded) — impact realized versus specimen potential. Percentile is relative to a registry of established collections (a high bar — it now spans large flagships down to smaller, more modest cohorts); realized impact saturates near 70 under the standardized scoring. Collections in the upper-left hold value their science has not yet fully exploited.
Impact is grounded in free, open, peer-reviewed sources — the NIH's Relative Citation Ratio (iCite) and OpenAlex field-weighted citation impact. Potential is a maintained, expert-curated valuation of each collection's specimens. No proprietary impact factors, no black boxes.
We'll value your collection and add it to the registry — and walk you through where it lands and what to do about the gap.